Menu
Currency
GWAS Study

Association of a Variant in VWA3A with Response to Anti-Vascular Endothelial Growth Factor Treatment in Neovascular AMD.

Grunin M, Beykin G, Rahmani E et al.

32106291 PubMed ID
GWAS Study Type
295 Participants
29 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

GM
Grunin M
BG
Beykin G
RE
Rahmani E
SR
Schweiger R
BG
Barel G
HS
Hagbi-Levi S
ES
Elbaz-Hayoun S
RB
Rinsky B
GM
Ganiel M
CS
Carmi S
HE
Halperin E
CI
Chowers I
Chapter II

Abstract

Summary of the research findings

Purpose: Anti-vascular endothelial growth factor (VEGF) therapy for neovascular AMD (nvAMD) obtains a variable outcome. We performed a genome-wide association study for anti-VEGF treatment response in nvAMD to identify variants potentially underlying such a variable outcome.

187 Israeli ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

295
Total Participants
GWAS
Study Type
Yes
Replicated
108 Israeli ancestry individuals
Replication Participants
European, Greater Middle Eastern (Middle Eastern, North African or Persian)
Ancestry
Israel
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.